5 completed, 1 terminated, 1 unknown. 4 Phase 1, 4 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 3, Terminated 1 |
| Phase 2 | 4 | Completed 4 |
| Phase 3 | 1 | Unknown 1 |
Follow Mologen AG: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combinatorial Therapy to Induce an HIV Remission Combination Intervention - HIV/AIDS | Phase 1 / Phase 2 | Completed | University of California, San Francisco | 11 | 2020-08-01 | 2026-08-28 |
| Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies MGN1703, Ipilimumab - Advanced Cancers, Melanoma | Phase 1 | Terminated | M.D. Anderson Cancer Center | 28 | 2016-05-11 | 2026-04-07 |
| Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment Usual Maintenance, MGN1703 treatment - Metastatic Colorectal Cancer | Phase 3 | Unknown | Mologen AG | 540 | 2014-09-01 | 2019-09-10 |
| Randomized Study of Maintenance Therapy With MGN1703 in Patients With SCLC MGN1703, Standard of care - Small Cell Lung Cancer | Phase 2 | Completed | Mologen AG | 103 | 2014-03-01 | 2018-11-15 |
| A Phase I Study to Assess Cardiac and General Safety and Pharmacokinetics of 60 mg MGN1703 MGN-Placebo, Placebo-MGN - Healthy | Phase 1 | Completed | Mologen AG | 14 | 2013-11-01 | 2014-05-19 |
| A Clinical Study to Assess Safety and Efficacy of a Tumor Vaccine in Patients With Advanced Renal Cell Carcinoma (ASET) MGN1601 - Stage IV Renal Cell Cancer | Phase 1 / Phase 2 | Completed | Mologen AG | 19 | 2010-11-01 | 2018-11-15 |
| Efficacy Study of a Maintenance Therapy With Immunomodulator MGN1703 in Patients With Advanced Colorectal Carcinoma MGN1703, Placebo - Advanced Colorectal Carcinoma | Phase 2 | Completed | Mologen AG | 59 | 2010-06-01 | 2014-06-20 |
Neoplasm Metastasis (2) · Acquired Immunodeficiency Syndrome (1) · Carcinoma, Renal Cell (1) · Colorectal Neoplasms (1) · Melanoma (1) · Recurrence (1) · Small Cell Lung Carcinoma (1)
MGN1703 (3) · Immunologic Factors (1) · Ipilimumab (1) · Standard of Care (1)
Germany (4) · Austria (3) · United States (3) · Belgium (2) · France (2) · Spain (2) · United Kingdom (2) · Czechia (1) · Estonia (1) · Italy (1) · Russia (1)
Carlos R Sanabria, MD (1) · David Cunningham, MD (1) · David S. Hong, MD (1) · Georg Pall, MD (1) · Hans-Joachim Schmoll (1) · Veerle Surmont, MD (1)
PMID 30137193, PMID 39959251, PMID 41326736
2009 (2), UM1AI164560 (1)